Patents by Inventor Jinliang GAO

Jinliang GAO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230143359
    Abstract: Disclosed in the present invention are a gene interference vector- and iron nanoparticle-based composition for killing cancer cells, and the use thereof. The composition comprises a gene interference vector and iron nanoparticles, wherein the gene interference vector is a CRISPR/Cas13a expression vector or microRNA expression vector controlled by a cancer cell specific promoter DMP, with the Cas13a-gRNA or microRNA expressed by the vector being able to inhibit, in a targeted manner, intracellular iron metabolism and the expression of reactive oxygen related genes, and the iron nanoparticles can be degraded after entering cells to produce iron ions and to increase the reactive oxygen level. The composition comprising the gene interference vector and the iron nanoparticles of the present invention can be used for preparing a new reagent for treating cancers.
    Type: Application
    Filed: January 15, 2021
    Publication date: May 11, 2023
    Applicant: SOUTHEAST UNIVERSITY
    Inventors: Jinke WANG, Jinliang Gao, Tao Luo
  • Patent number: 10900028
    Abstract: The invention relates to the field of bioengineering. In particular, the invention relates to a heparinase-producing Pseudomonas stutzeri strain and a heparinase derived therefrom. Furthermore, the invention relates to the preparation and use of the heparinase.
    Type: Grant
    Filed: December 22, 2017
    Date of Patent: January 26, 2021
    Assignee: Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
    Inventors: Li Li, Jiake Bai, Jinliang Gao, Xiaolai Ma
  • Publication number: 20200123524
    Abstract: The invention relates to the field of bioengineering. In particular, the invention relates to a heparinase-producing Pseudomonas stutzeri strain and a heparinase derived therefrom. Furthermore, the invention relates to the preparation and use of the heparinase.
    Type: Application
    Filed: December 22, 2017
    Publication date: April 23, 2020
    Applicant: Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
    Inventors: Li LI, Jiake BAI, Jinliang GAO, Xiaolai MA